Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ignace Vergote

Showing results (391-400 of 578) with videos related to

Pageof 58
Sort By:
American Journal of Obstetrics and Gynecology|January 24, 2016
Predicting the risk of malignancy in adnexal masses based on the Simple Rules from the International Ovarian Tumor Analysis groupDirk Timmerman, Ben Van Calster, Antonia Testa, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 9, 2010
European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and pharmaceutical companiesIgnace Vergote, Eric Pujade-Lauraine, Sandro Pignata, et al.
European Journal of Cancer (Oxford, England : 1990)|May 20, 2017
Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) ConsortiumIlary Ruscito, Dan Cacsire Castillo-Tong, Ignace Vergote, et al.
Journal of the National Cancer Institute|December 29, 2020
Concordance Between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 TrialCéline Callens, Dominique Vaur, Isabelle Soubeyran, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 11, 2021
ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumorsDirk Timmerman, François Planchamp, Tom Bourne, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 1, 2019
European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer SurgeryDenis Querleu, François Planchamp, Luis Chiva, et al.
Gynecologic Oncology|December 2, 2014
Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 TrialAnne Floquet, Ignace Vergote, Nicoletta Colombo, et al.
Gynecologic Oncology|June 23, 2022
Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancerCarlotta Keunecke, Hagen Kulbe, Felix Dreher, et al.
Oncogene|July 4, 2023
Amyloid-like p53 as prognostic biomarker in serous ovarian cancer-a study of the OVCAD consortiumNicole Heinzl, Elisabeth Maritschnegg, Katarzyna Koziel, et al.
Gynecologic Oncology|September 22, 2016
Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice GuidelineAlexi A Wright, Kari Bohlke, Deborah K Armstrong, et al.
Pageof 58

Showing results (391-400 of 578) with videos related to

Sort By:
Pageof 58
American Journal of Obstetrics and Gynecology|January 24, 2016
Predicting the risk of malignancy in adnexal masses based on the Simple Rules from the International Ovarian Tumor Analysis groupDirk Timmerman, Ben Van Calster, Antonia Testa, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 9, 2010
European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and pharmaceutical companiesIgnace Vergote, Eric Pujade-Lauraine, Sandro Pignata, et al.
European Journal of Cancer (Oxford, England : 1990)|May 20, 2017
Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) ConsortiumIlary Ruscito, Dan Cacsire Castillo-Tong, Ignace Vergote, et al.
Journal of the National Cancer Institute|December 29, 2020
Concordance Between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 TrialCéline Callens, Dominique Vaur, Isabelle Soubeyran, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 11, 2021
ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumorsDirk Timmerman, François Planchamp, Tom Bourne, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 1, 2019
European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer SurgeryDenis Querleu, François Planchamp, Luis Chiva, et al.
Gynecologic Oncology|December 2, 2014
Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 TrialAnne Floquet, Ignace Vergote, Nicoletta Colombo, et al.
Gynecologic Oncology|June 23, 2022
Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancerCarlotta Keunecke, Hagen Kulbe, Felix Dreher, et al.
Oncogene|July 4, 2023
Amyloid-like p53 as prognostic biomarker in serous ovarian cancer-a study of the OVCAD consortiumNicole Heinzl, Elisabeth Maritschnegg, Katarzyna Koziel, et al.
Gynecologic Oncology|September 22, 2016
Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice GuidelineAlexi A Wright, Kari Bohlke, Deborah K Armstrong, et al.
Pageof 58